ARDS Clinical Trial
— COMIX-ROfficial title:
Comparison of Volume Assist Control, Dual Mode and Airway Pressure Release Ventilation: A Physiological Study
Verified date | January 2024 |
Source | University Hospital, Angers |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The aim of the COMIX-R study is to assess the short term physiological effects of 3 ventilation strategies for adult patients with ARDS admitted to intensive care unit
Status | Completed |
Enrollment | 20 |
Est. completion date | October 26, 2022 |
Est. primary completion date | October 26, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - 18 years or older - Invasive mechanical ventilation on tracheal probe - Acute respiratory distress syndrome, as defined by Berlin conference consensus, during hospitalization in intensive care, - Recovery phase of acute respiratory distress syndrome: spontaneous ventilation representing from 20 to 30% of ventilation in APRV mode. - No severe acidosis (pH> 7.30) - Patient affiliated to or beneficiary of a health care plan - Express consent of the patient or his/her SDM Exclusion Criteria: - Pneumothorax - Contraindication to the insertion of a nasogastric tube with an esophageal balloon - Contraindication to the use of Electrical impedance tomography (pacemaker) - Pregnancy, lactating or parturient woman |
Country | Name | City | State |
---|---|---|---|
France | University hospital | Angers |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Angers |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | change of PaO2 (mmHg) | Arterial partial pressure of dioxygen Of note: As it is a physiological study, all the primary and secondary outcomes will be analyzed with the same importance. | 15 minutes, 1 hour, 1hour and 45 minutes, 2 hour and 30 minutes | |
Secondary | -Respiratory rate variability | variability of rate (per minute) | 15 minutes, 1 hour, 1hour and 45 minutes, 2 hour and 30 minutes | |
Secondary | -expiratory and inspiratory transpulmonary pressure | calculated with the esophageal pressure (cm H20) | 15 minutes, 1 hour, 1hour and 45 minutes, 2 hour and 30 minutes | |
Secondary | -ventilation distribution in the lungs | Electrical impedance tomography (EIT) assess distribution of tidal volume and of end-expiratory lung volume (EELV) (delta Z, IU) | 15 minutes, 1 hour, 1hour and 45 minutes, 2 hour and 30 minutes | |
Secondary | -other arterial parameters of hematosis | pH, PaO2, PaCo2 (mmHg) | 15 minutes, 1 hour, 1hour and 45 minutes, 2 hour and 30 minutes | |
Secondary | -Work of breathing (WOB) | calculated with esophageal pressure (Kg/m) | 15 minutes, 1 hour, 1hour and 45 minutes, 2 hour and 30 minutes | |
Secondary | -Pressure time product (PTP) | -Pressure time product (PTP) calculated with esophageal pressure (cmH2O.s.min-1) | 15 minutes, 1 hour, 1hour and 45 minutes, 2 hour and 30 minutes | |
Secondary | -P0.1 | pressure measured during the first 100 ms after an occlusion (cm H20) | 15 minutes, 1 hour, 1hour and 45 minutes, 2 hour and 30 minutes | |
Secondary | -PEEPi | intrinsic positive end-expiratory pressure (cm H20) | 15 minutes, 1 hour, 1hour and 45 minutes, 2 hour and 30 minutes | |
Secondary | MAP | mean arterial pressure | 15 minutes, 1 hour, 1hour and 45 minutes, 2 hour and 30 minutes | |
Secondary | HR | heart rate (beats per minute) | 15 minutes, 1 hour, 1hour and 45 minutes, 2 hour and 30 minutes | |
Secondary | -Respiratory comfort | visual analogic scale | 15 minutes, 1 hour, 1hour and 45 minutes, 2 hour and 30 minutes | |
Secondary | -Patient-ventilator asynchronies | numbers of asynchronies analyzed on screen | 15 minutes, 1 hour, 1hour and 45 minutes, 2 hour and 30 minutes | |
Secondary | -Tidal volume variability | variability of Tidal volume (mL) | 15 minutes, 1 hour, 1hour and 45 minutes, 2 hour and 30 minutes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04435613 -
Clinical and Physiological Assessment of a Nearly Ultra-protective Lung Ventilation Strategy: A Quasi-experimental Preliminary Study in ARDS Patients
|
N/A | |
Enrolling by invitation |
NCT05020210 -
Effect of Early Treatment With Sivelestat Sodium in ARDS Patients
|
||
Completed |
NCT04468971 -
REgulatory T Cell infuSion fOr Lung Injury Due to COVID-19 PnEumonia
|
Phase 1 | |
Completed |
NCT04505592 -
Tenecteplase in Patients With COVID-19
|
Phase 2 | |
Completed |
NCT04493242 -
Extracellular Vesicle Infusion Treatment for COVID-19 Associated ARDS
|
Phase 2 | |
Withdrawn |
NCT04909879 -
Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Non-COVID-19 Acute Respiratory Distress Syndrome
|
Phase 2 | |
Completed |
NCT02265198 -
Relationship of Pulmonary Contusion to Pulmonary Inflammation and Incidence of Acute Respiratory Distress Syndrome
|
N/A | |
Completed |
NCT01949272 -
Optimization of PEEP for Alveolar Recruitment in ARDS
|
N/A | |
Not yet recruiting |
NCT01668368 -
Goal Directed Mechanical Ventilation Aimed at Optimal Lung Compliance
|
N/A | |
Completed |
NCT01881061 -
Lung Sonography in Patients With Acute Respiratory Distress Syndrome in Intensive Care Unit
|
N/A | |
Completed |
NCT00808691 -
Microcirculation and Oxidative Stress in Critical Ill Patients in Surgical Intensive Care Unit
|
N/A | |
Completed |
NCT05035589 -
The Effect of Tocilizumab on Procalcitonin and Other Biochemical and Clinical Markers in the Setting of COVID-19 Pneumonia
|
||
Recruiting |
NCT04764032 -
Right Ventricular Dysfunction in Ventilated Patients With COVID-19
|
||
Completed |
NCT04556513 -
Functional Recovery From Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19: Influence of Socio-Economic Status
|
||
Recruiting |
NCT06036056 -
NMR Based Metabolomics Kinetics in ARDS Patients
|
||
Recruiting |
NCT04503876 -
Effects of End-expiratory Positive Pressure Optimization in Intubated Patients With Healthy Lung or Acute Respiratory Distress Syndrome
|
N/A | |
Recruiting |
NCT04643691 -
Losartan and Spironolactone Treatment for ICU Patients With COVID-19 Suffering From ARDS
|
Phase 2 | |
Completed |
NCT04395911 -
Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections
|
N/A | |
Not yet recruiting |
NCT05341687 -
Prognostic Value of Respiratory System Compliance Under VV-ECMO on 180-day Mortality in COVID-19 ARDS.
|
||
Recruiting |
NCT05056090 -
Effect of Prone Positioning on Mortality in Patients With Mild to Moderate Acute Respiratory Distress Syndrome.
|
N/A |